These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21115057)

  • 1. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.
    Micoli F; Rondini S; Pisoni I; Proietti D; Berti F; Costantino P; Rappuoli R; Szu S; Saul A; Martin LB
    Vaccine; 2011 Jan; 29(4):712-20. PubMed ID: 21115057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.
    Rondini S; Micoli F; Lanzilao L; Hale C; Saul AJ; Martin LB
    Clin Vaccine Immunol; 2011 Mar; 18(3):460-8. PubMed ID: 21248155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
    J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
    Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
    Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
    Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
    Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
    Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
    Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
    Singh M; Ganguly NK; Kumar L; Vohra H
    Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi.
    Rondini S; Micoli F; Lanzilao L; Pisoni I; Di Cioccio V; Saul AJ; Martin LB
    J Infect Dev Ctries; 2012 Nov; 6(11):763-73. PubMed ID: 23277501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM
    Micoli F; Bjarnarson SP; Arcuri M; Aradottir Pind AA; Magnusdottir GJ; Necchi F; Di Benedetto R; Carducci M; Schiavo F; Giannelli C; Pisoni I; Martin LB; Del Giudice G; MacLennan CA; Rappuoli R; Jonsdottir I; Saul A
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24443-24449. PubMed ID: 32900928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
    Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
    Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Vi conjugate - a new generation of typhoid vaccine.
    Szu SC
    Expert Rev Vaccines; 2013 Nov; 12(11):1273-86. PubMed ID: 24156285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcutaneous Vaccination with Conjugate Typhoid Vaccine Vi-DT Induces Systemic, Mucosal, and Memory Anti-Polysaccharide Responses.
    Bhuiyan MS; Kalsy A; Arifuzzaman M; Charles RC; Harris JB; Calderwood SB; Qadri F; Ryan ET
    Am J Trop Med Hyg; 2020 Sep; 103(3):1032-1038. PubMed ID: 32720632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection in a mouse peritonitis model mediated by iron-regulated outer-membrane protein of Salmonella typhi coupled to its Vi antigen.
    Chibber S; Bhardwaj SB
    J Med Microbiol; 2004 Jul; 53(Pt 7):705-709. PubMed ID: 15184544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
    van Damme P; Kafeja F; Anemona A; Basile V; Hilbert AK; De Coster I; Rondini S; Micoli F; Qasim Khan RM; Marchetti E; Di Cioccio V; Saul A; Martin LB; Podda A
    PLoS One; 2011; 6(9):e25398. PubMed ID: 21980445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.